Boehringer seeks approval of lung disease drug after second Phase III success
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
aboutamazon1d
All the health care options offered by Amazon—primary care, virtual care, pharmacy, and more
Amazon Health Services offers you curated choices, convenience, clarity of cost, and continuity of care on your path to get and stay healthy.
BioSpace1d
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
manilatimes1d
Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...
Boehringer Ingelheim Limited: Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...
Business Wire5d
Boehringer Ingelheim India and EMRI Green Health Services a GVK Enterprise Sign MoU to Transform Pre-hospital Stroke Care in India
Boehringer Ingelheim India and EMRI Green Health Services a GVK Enterprise Sign MoU to Transform Pre-hospital Stroke Care in India ...